Estimates of the size of the 2013 U.S. retail market for hemp products were released by the Hemp Industries Association (HIA). The estimated total retail sales of hemp food and body care products in 2013 totaled at around $184 million. The sales primarily consisted of items such as milk, seeds, soaps and lotions which have been very popular thanks to the Farm Bill, which allowed hemp to be grown domestically. Sales of clothing, paper, auto parts, building materials and many other products totaled to approximately $581 million.
However, there is one use of hemp that has not been accounted for and that is energy shots. FBEC Worldwide Inc (OTCMKTS:FBEC) is a unique beverage company that works to provide proprietary products geared towards special target markets internationally and domestically. The company is committed to increasing its market size through creative marketing and is committed to providing customer satisfaction.
On November 6, 2015, FBEC Worldwide Inc (OTCMKTS:FBEC) announced that their product, the WolfShot(TM) Hemp Energy(TM), was now available to sell online. The products were available on Ebay, Alibaba, and even Amazon. Ten days later, on November 16, 2015, the company announced that the WolfShot (TM) sold out on Amazon over the weekend. In addition, the product received the #1 new best seller rating. Here is what CEO Jason Spatafora said: “Our early success on Amazon has resulted in strong interest from potential distributors. Receiving a #1 New Best Seller rating for energy shots over the weekend will give me leverage in distribution negotiations. We are well stocked to handle upcoming production.”
All of the great news that the company has been announcing has also been reflecting in its stock. On October 27th, FBEC saw a low of $0.0262 and traded with a volume of 404k. Since this time the stock has begun to increase to highs of as much as $0.07. As FBEC Worldwide continues to expand, and as hemp becomes more widespread, it is possible to see the stock grow in the upcoming months.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.